Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0801
    +0.0008 (+0.08%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2634
    +0.0012 (+0.09%)
     
  • USD/JPY

    151.2030
    -0.1690 (-0.11%)
     
  • Bitcoin USD

    70,087.38
    -693.80 (-0.98%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

The Dark Side of Cannabis Legalization and one Biotech Company's Solution

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.

Photo credits: Tim Foster

As of July 2021, 18 states have legalized recreational marijuana while another 18 have legalized cannabis solely for medical purposes. Meanwhile, Florida, Connecticut and Hawaii all have introduced legislation supporting legalization.

As cannabis becomes decriminalized across the country, one of the unintended consequences is an increase in use — and inevitably, an increase in cannabis intoxication.

Cannabis-associated emergency department visits have gone up by a compound annual growth rate (CAGR) of 15% since the first states legalized the substance in 2012. Estimates suggest that more than 1.7 million emergency room visits in 2018 were associated with THC. Trends of adults and children accidentally consuming high concentrations of THC and synthetic THC are likely to persist.

Public discourse around the symptoms of cannabis intoxication tend to be minimized, especially in comparison to other narcotics where overdoses frequently result in death. Nevertheless, cannabis intoxication can be incredibly distressing. Symptoms include extreme anxiety, panic attacks, psychotic reactions, uncontrollable shaking or even seizures. Synthetic cannabis symptoms are more severe.

According to emergency room physicians, patients can’t wait for an antidote and neither can doctors, but unfortunately, the market has lacked an efficient solution for cannabis intoxication.

Anebulo as a Treatment for Cannabis Intoxication

Anebulo Pharmaceuticals (NASDAQ: ANEB) is a clinical stage biotech company whose lead product, ANEB-001, is a promising antidote for cannabis intoxication. Anebulo’s development is significant because there are currently no approved medical treatments for alleviating the symptoms of cannabis intoxication.

Instead, patients who head into the emergency department with cannabis intoxication have no other option but wait in the hospital until they become sober — taking up valuable resources and delaying other patients.

Anebulo’s solution is intended to work fast and alleviate the most distressing symptoms of overdose — especially those caused by accidental ingestion of edible products and synthetic marijuana.

The ANEB-001 treatment works by blocking the effects of THC at the brain’s CB1 receptor. In as little as 1 hour, patients could receive relief from anxiety, decreased psychosis, normalization of heartbeat and an overall decrease in feeling high.

How Companies Like Anebulo will Continue to Shape the Cannabis Industry

Much of the investment focus within the cannabis sector centers on production, distribution and retail cannabis brands. However, as nationwide legalization increases, so will cannabis-related emergency room visits and the need for a viable antidote.

While there’s not much that can be done to prevent cannabis intoxication, Anebulo’s solution offers the potential for fast, safe treatment that could help patients and people struggling with addiction as well as allow physicians to perform their work more effectively.
Anebulo is a publicly traded company based in Texas. You can learn more about Anebulo’s stock data, financial reports and investor relations here.

The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement